USP35 and ovarian carcinoma: Zhang et al. described the high expression of deubiquitinase USP35 in cisplatin-resistant ovarian cancer cells, and demonstrated that USP35 directly deubiquitinated and inactivated STING, but not cGAS, reducing IFN signaling and ultimately leading to reduced infiltration of CD8+ T cells [133].